Showing results (51-60 of 405) with videos related to
Sort By:
Pageof 41
Therapeutic Advances in Drug Safety|August 2, 2014
Benefits versus risks of latest therapies in multiple sclerosis: a perspective reviewDaniel Ontaneda, Daniela Di CapuaExpert Review of Clinical Pharmacology|November 26, 2011
Potential mechanisms of efficacy and adverse effects in the use of fingolimod (FTY720)Daniel Ontaneda, Jeffrey A CohenDegenerative Neurological and Neuromuscular Disease|July 28, 2018
Treating primary-progressive multiple sclerosis: potential of ocrelizumab and review of B-cell therapiesJenny J Feng, Daniel OntanedaContinuum (Minneapolis, Minn.)|August 7, 2013
Multiple sclerosis treatment: risk mitigationDaniel Ontaneda, Robert J FoxThe International Journal of Neuroscience|October 12, 2013
Is neuromyelitis optica with advanced age of onset a paraneoplastic disorder?Daniel Ontaneda, Robert J FoxMultiple Sclerosis (Houndmills, Basingstoke, England)|November 9, 2023
Extended interval dosing of ocrelizumab in patients with multiple sclerosis is not associated with meaningful differences in disease activityNicole Bou Rjeily, Kathryn C Fitzgerald, Ellen M MowryComprehensive Ophthalmology Update|March 31, 2007
Multiple sclerosis and the ophthalmologistEllen M Mowry, Laura J Balcer, Steven L GalettaNature Clinical Practice. Neurology|June 6, 2007
Technology insight: can neuroimaging provide insights into the role of ischemia in Baló's concentric sclerosis?Ellen M Mowry, John H Woo, Beau M AncesNature Clinical Practice. Neurology|June 6, 2007
Baló's concentric sclerosis presenting as a stroke-like syndromeEllen M Mowry, John H Woo, Beau M AncesBrain Communications|March 2, 2023
Arbaclofen extended-release tablets for spasticity in multiple sclerosis: open-label extension studyDarin T Okuda, Daniel Kantor, Mark Jaros, et al.Pageof 41